Fresenius Medical Care AG & Co. (FMS)
Stock Price Chart
Key Info
| Market Cap | 24.74B |
| Revenue (ttm) | 17.48B |
| Net Income (ttm) | 1.20B |
| Shares Out | 585.67M |
| EPS (ttm) | 3.69 |
| PE Ratio | 11.45 |
| Forward PE | 13.64 |
| Dividend | $0.72 |
| Dividend Yield | 1.70% |
Stock Quote
| Trading Day | November 23 |
| Last Price | $42.24 |
| Previous Close | $42.47 |
| Change ($) | -0.23 |
| Change (%) | -0.54% |
| Day's Open | 42.65 |
| Day's Range | 41.94 - 42.67 |
| Day's Volume | 115,866 |
| 52-Week Range | 29.17 - 46.55 |
More Stats
| Market Cap | 24.74B |
| Enterprise Value | 37.51B |
| Earnings Date (est) | Feb 23, 2021 |
| Ex-Dividend Date | Aug 28, 2020 |
| Shares Outstanding | 585.67M |
| Float | n/a |
| EPS (basic) | 1.98 |
| EPS (diluted) | 3.69 |
| FCF / Share | 2.37 |
| Dividend | $0.72 |
| Dividend Yield | 1.70% |
| Earnings Yield | 8.74% |
| FCF Yield | 5.88% |
| Payout Ratio | 33.10% |
| Shares Short | 821,165 |
| Short Ratio | 3.05 |
| Short % of Float | n/a |
| Beta | 1.03 |
| PE Ratio | 11.45 |
| Forward PE | 13.64 |
| P/FCF Ratio | 17.02 |
| PS Ratio | 1.42 |
| PB Ratio | 1.83 |
| Revenue | 17.48B |
| Operating Income | 2.20B |
| Net Income | 1.20B |
| Free Cash Flow | 1.45B |
| Net Cash | -12.77B |
| Net Cash / Share | -21.81 |
| Gross Margin | 29.91% |
| Operating Margin | 12.56% |
| Profit Margin | 6.90% |
| FCF Margin | 8.32% |
| ROA | 4.54% |
| ROE | 12.23% |
| ROIC | 11.70% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17,477 | 16,547 | 17,784 | 16,570 | 15,455 | 15,832 | 14,610 | 13,800 | 12,571 | 11,844 |
| Revenue Growth | 5.62% | -6.95% | 7.33% | 7.21% | -2.38% | 8.36% | 5.87% | 9.78% | 6.13% | - |
| Gross Profit | 5,396 | 5,155 | 6,018 | 5,616 | 5,177 | 4,996 | 4,738 | 4,601 | 4,152 | 3,835 |
| Operating Income | 2,196 | 2,964 | 2,295 | 2,350 | 2,100 | 2,230 | 2,230 | 2,201 | 2,044 | 1,915 |
| Net Income | 1,200 | 1,982 | 1,280 | 1,144 | 955 | 1,045 | 1,110 | 1,187 | 1,071 | 979 |
| Shares Outstanding | 307 | 306 | 306 | 305 | 301 | 301 | 303 | 300 | 298 | 296 |
| Earnings Per Share | 1.98 | 3.23 | 2.08 | 1.87 | 1.57 | 1.73 | 1.83 | 1.94 | 1.76 | 1.62 |
| EPS Growth | -38.6% | 55.05% | 11.53% | 19.17% | -9.28% | -5.48% | -5.68% | 10.26% | 8.33% | - |
| Dividend Per Share | 0.66 | 0.63 | 0.36 | 0.44 | 0.44 | 0.53 | 0.49 | 0.91 | 0.95 | 0.82 |
| Dividend Growth | 3.64% | 76.54% | -18.64% | 0.46% | -17.82% | 8.78% | -46.21% | -4.11% | 16.56% | - |
| Operating Cash Flow | 2,567 | 2,062 | 2,192 | 1,932 | 1,767 | 1,861 | 2,035 | 2,039 | 1,446 | 1,368 |
| Capital Expenditures | -1,113 | -1,003 | -841 | -915 | -843 | -920 | -728 | -666 | -571 | -508 |
| Free Cash Flow | 1,454 | 1,059 | 1,351 | 1,017 | 923 | 941 | 1,307 | 1,373 | 876 | 861 |
| Cash & Equivalents | 1,008 | 2,146 | 978 | 709 | 550 | 634 | 683 | 688 | 457 | 523 |
| Total Debt | 13,782 | 7,546 | 7,448 | 8,132 | 8,646 | 9,466 | 8,417 | 8,298 | 7,211 | 5,880 |
| Net Cash / Debt | -12,775 | -5,401 | -6,470 | -7,423 | -8,097 | -8,832 | -7,735 | -7,610 | -6,754 | -5,357 |
| Assets | 32,935 | 26,242 | 24,025 | 25,504 | 25,365 | 25,381 | 23,120 | 22,326 | 19,533 | 17,095 |
| Liabilities | 19,707 | 13,340 | 13,197 | 14,452 | 13,841 | 14,528 | 12,987 | 12,595 | 11,061 | 9,291 |
| Book Value | 11,958 | 11,758 | 9,820 | 9,978 | 9,887 | 9,443 | 9,235 | 8,943 | 7,902 | 7,377 |
Company Profile
Company Details
| Full Name | Fresenius Medical Care AG & Co. |
| Country | Germany |
| Employees | 126,463 |
| CEO | Rice Powell |
Stock Information
| Ticker Symbol | FMS |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Unique Identifier | NYSE: FMS |
| IPO Date | September 19, 1996 |
Description
Fresenius Medical Care AG & KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.